{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=End-stage+Renal+Disease&page=6",
    "query": {
      "condition": "End-stage Renal Disease",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 756,
    "total_pages": 76,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=End-stage+Renal+Disease&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=End-stage+Renal+Disease&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T09:04:31.342Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00062699",
      "title": "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End-Stage Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Zemplar (paricalcitol injection)",
          "type": "DRUG"
        },
        {
          "name": "Calcijex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 2200,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-08-02",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 60,
      "location_summary": "Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Pablo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062699"
    },
    {
      "nct_id": "NCT05614115",
      "title": "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-stage Kidney Disease",
        "Kidney Disease, Chronic",
        "Dialysis",
        "Diabetic",
        "Non-diabetic",
        "Kidney Dysfunction",
        "Kidney Failure",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2023-03-21",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614115"
    },
    {
      "nct_id": "NCT04534114",
      "title": "Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Fesomersen sodium (BAY2976217)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2020-09-04",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 9,
      "location_summary": "Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Saint Ann",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04534114"
    },
    {
      "nct_id": "NCT03934736",
      "title": "HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease on Hemodialysis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-04-22",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 20,
      "location_summary": "Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934736"
    },
    {
      "nct_id": "NCT03241511",
      "title": "Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Periodontitis",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "UConn Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2017-11-07",
      "completion_date": "2020-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03241511"
    },
    {
      "nct_id": "NCT03873038",
      "title": "Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Dialysis",
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "MK-2060",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 38,
      "start_date": "2019-04-29",
      "completion_date": "2021-12-20",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03873038"
    },
    {
      "nct_id": "NCT00294866",
      "title": "Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Failure"
      ],
      "interventions": [
        {
          "name": "Paricalcitol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fresenius Medical Care North America",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2006-03",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2010-04-08",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 6,
      "location_summary": "Evergreen Park, Illinois • Kalamazoo, Michigan • West Orange, New Jersey + 3 more",
      "locations": [
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        },
        {
          "city": "West Orange",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00294866"
    },
    {
      "nct_id": "NCT00951353",
      "title": "Immune Development in Pediatric Transplantation (IMPACT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Failure",
        "End Stage Renal Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "1 Year to 20 Years"
      },
      "enrollment_count": 125,
      "start_date": "2009-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951353"
    },
    {
      "nct_id": "NCT01612429",
      "title": "Carbamylation in Renal Disease-modulation With Amino Acid Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "End Stage Renal Failure on Dialysis"
      ],
      "interventions": [
        {
          "name": "Amino acid supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-10",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01612429"
    },
    {
      "nct_id": "NCT02052310",
      "title": "Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia in Incident Dialysis Patients"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1043,
      "start_date": "2014-02-11",
      "completion_date": "2018-09-21",
      "has_results": true,
      "last_update_posted_date": "2021-10-01",
      "last_synced_at": "2026-10-13T09:04:31.342Z",
      "location_count": 30,
      "location_summary": "Chula Vista, California • La Mesa, California • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Lauderdale Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052310"
    }
  ]
}